Top Markets
#1 QuantixAI QuantixAI +105.36%
#2 龙虾 (Lobster) 龙虾 (Lobster) +47.86%
#3 MetaDAO MetaDAO +29.20%
#4 Rain Rain +23.12%
#5 Bedrock Bedrock +19.74%
#6 Pons Pons +18.81%
#7 Prom Prom +17.17%
#8 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +16.51%
#9 Ontology Gas Ontology Gas +15.02%
#10 Humanity Humanity +14.89%
Coin of the day
QuantixAI QuantixAI
Cài đặt
Ngôn ngữ
TIếNG VIệT
Tiền tệ
USD
Chủ đề
Heidelberg Pharma AG Heidelberg Pharma AG

Heidelberg Pharma AG

HPHA
Xếp hạng trong cổ phiếu #20135
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a... Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
Giá cổ phiếu
$2.99
Vốn hóa thị trường
$139.84M
Thay đổi (1 ngày)
-0.40%
Thay đổi (1 năm)
-41.27%
Quốc gia
DE
Giao dịch Heidelberg Pharma AG (HPHA)

Danh mục

Healthcare
Lịch sử giá cổ phiếu của Heidelberg Pharma AG (HPHA)
Giá đóng cửa cao nhất: $2.99 vào 2026-08-01

Giá đóng cửa thấp nhất: $68.95 vào 2006-11-01
Lịch sử giá cổ phiếu của Heidelberg Pharma AG từ 2006 đến 2026
Hiệu suất giá cổ phiếu hàng năm
Năm Hiệu suất
2026 (TTM) 8.96%
2025 24.78%
2024 -34.62%
2023 -35.99%
2022 6.20%
2021 -25.03%
2020 214.32%
2019 -21.18%
2018 -12.11%
2017 65.41%
2016 10.32%
2015 -15.82%
2014 -69.90%
2013 54.37%
2012 -75.41%
2011 -18.87%
2010 8.30%
2009 41.38%
2008 -53.24%
2007 -52.21%
2006 0.00%
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
Công ty Giá cổ phiếu Thay đổi 1năm% Quốc gia
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $553.09 42.20%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.02K 50.56%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $158.64 525.80%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.47 -12.71%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $772.27 8.67%
CH